Targeting insulin-like growth factor pathways

D. Yee

doi:10.1038/sj.bjc.6602963

Targeting insulin-like growth factor pathways

D. Yee

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Short survey › peer-review

95 Scopus citations

Abstract

Some cancer cells depend on the function of specific molecules for their growth, survival, and metastatic potential. Targeting of these critical molecules has arguably been the best therapy for cancer as demonstrated by the success of tamoxifen and trastuzumab in breast cancer. This review will evaluate the type I IGF receptor (IGF-IR) as a potential target for cancer therapy. As new drugs come forward targeting this receptor system, several issues will need to be addressed in the early clinical trials using these agents.

Original language	English (US)
Pages (from-to)	465-468
Number of pages	4
Journal	British Journal of Cancer
Volume	94
Issue number	4
DOIs	https://doi.org/10.1038/sj.bjc.6602963
State	Published - Feb 27 2006

Bibliographical note

Funding Information:
This work was supported by Public Health Service grants CA89652, CA74285, and Cancer Center Support Grant P30 CA77398.

Keywords

Insulin-like growth factor receptors
Insulin-like growth factors
Monoclonal antibodies
Tyrosine kinase inhibitors

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1038/sj.bjc.6602963

Find It

Find It at U of M Libraries

Cite this

@article{22b5a70dfc304c1388892c7177cfc829,

title = "Targeting insulin-like growth factor pathways",

abstract = "Some cancer cells depend on the function of specific molecules for their growth, survival, and metastatic potential. Targeting of these critical molecules has arguably been the best therapy for cancer as demonstrated by the success of tamoxifen and trastuzumab in breast cancer. This review will evaluate the type I IGF receptor (IGF-IR) as a potential target for cancer therapy. As new drugs come forward targeting this receptor system, several issues will need to be addressed in the early clinical trials using these agents.",

keywords = "Insulin-like growth factor receptors, Insulin-like growth factors, Monoclonal antibodies, Tyrosine kinase inhibitors",

author = "D. Yee",

note = "Funding Information: This work was supported by Public Health Service grants CA89652, CA74285, and Cancer Center Support Grant P30 CA77398.",

year = "2006",

month = feb,

day = "27",

doi = "10.1038/sj.bjc.6602963",

language = "English (US)",

volume = "94",

pages = "465--468",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - Targeting insulin-like growth factor pathways

AU - Yee, D.

N1 - Funding Information: This work was supported by Public Health Service grants CA89652, CA74285, and Cancer Center Support Grant P30 CA77398.

PY - 2006/2/27

Y1 - 2006/2/27

N2 - Some cancer cells depend on the function of specific molecules for their growth, survival, and metastatic potential. Targeting of these critical molecules has arguably been the best therapy for cancer as demonstrated by the success of tamoxifen and trastuzumab in breast cancer. This review will evaluate the type I IGF receptor (IGF-IR) as a potential target for cancer therapy. As new drugs come forward targeting this receptor system, several issues will need to be addressed in the early clinical trials using these agents.

AB - Some cancer cells depend on the function of specific molecules for their growth, survival, and metastatic potential. Targeting of these critical molecules has arguably been the best therapy for cancer as demonstrated by the success of tamoxifen and trastuzumab in breast cancer. This review will evaluate the type I IGF receptor (IGF-IR) as a potential target for cancer therapy. As new drugs come forward targeting this receptor system, several issues will need to be addressed in the early clinical trials using these agents.

KW - Insulin-like growth factor receptors

KW - Insulin-like growth factors

KW - Monoclonal antibodies

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=33344467985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33344467985&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6602963

DO - 10.1038/sj.bjc.6602963

M3 - Short survey

C2 - 16450000

AN - SCOPUS:33344467985

SN - 0007-0920

VL - 94

SP - 465

EP - 468

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 4

ER -

Targeting insulin-like growth factor pathways

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this